Bullous Pemphigoid Associated with Cemiplimab Therapy in a Patient with Locally Advanced Cutaneous Squamous Cell Carcinoma

Overview

Journal JAAD Case Rep

Specialty Dermatology

Date 2020 Mar 10

PMID 32149176

Citations 7

Authors

Cesar A Virgen

Tuyet A Nguyen

Cosimo Di Raimondo

Arya Amini

Kim A Margolin

Vishwas Parekh

Farah R Abdulla

Badri Modi

Affiliations

Soon will be listed here.

Citing Articles

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.

Pach J, Valido K, Belzer A, Leventhal J Am J Clin Dermatol. 2024; 25(4):595-607.

PMID: 38767827 DOI: 10.1007/s40257-024-00866-z.

Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.

Mital R, Otto T, Savu A, Baumrin E, Cardones A, Carlesimo M Int J Dermatol. 2023; 62(8):1020-1025.

PMID: 37203799 PMC: 11250051. DOI: 10.1111/ijd.16714.

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.

Shalata W, Weissmann S, Gabay S, Sheva K, Abu Saleh O, Abu Jama A Cancers (Basel). 2022; 14(21).

PMID: 36358869 PMC: 9656349. DOI: 10.3390/cancers14215451.

Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Niebel D, Wilsmann-Theis D, Bieber T, Berneburg M, Wenzel J, Braegelmann C Dermatopathology (Basel). 2022; 9(1):60-81.

PMID: 35323203 PMC: 8947168. DOI: 10.3390/dermatopathology9010010.

Self-resolving bullous pemphigoid induced by cemiplimab.

Molle M, Capurro N, Herzum A, Micalizzi C, Cozzani E, Parodi A Dermatol Ther. 2022; 35(6):e15466.

PMID: 35320611 PMC: 9285614. DOI: 10.1111/dth.15466.

References

Weber J, Yang J, Atkins M, Disis M . Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015; 33(18):2092-9. PMC: 4881375. DOI: 10.1200/JCO.2014.60.0379. View

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page D . Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res. 2016; 4(5):383-9. PMC: 5241697. DOI: 10.1158/2326-6066.CIR-15-0123. View

Damsky W, Kole L, Tomayko M . Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016; 2(6):442-444. PMC: 5144742. DOI: 10.1016/j.jdcr.2016.05.009. View

Lacouture M, Sibaud V . Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018; 19(Suppl 1):31-39. PMC: 6244569. DOI: 10.1007/s40257-018-0384-3. View

Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R . Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. J Am Acad Dermatol. 2019; 81(1):179-186. DOI: 10.1016/j.jaad.2019.03.049. View